LDLR and Insulin resistance: The results have demonstrated that LPSF/GQ-02 was effective in decreasing the risk factors associated with the development of atherosclerosis, such as insulin resistance and inflammation, and consequently reducing atherosclerotic plaque in mice without the LDL receptor (LDLR-/-) [24].